At the time of writing, Intra-Cellular Therapies Inc [ITCI] stock is trading at $72.37, up 0.51%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ITCI shares have gain 9.85% over the last week, with a monthly amount glided 7.68%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Intra-Cellular Therapies Inc [NASDAQ: ITCI] stock has seen the most recent analyst activity on January 03, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $83. Previously, TD Cowen started tracking the stock with Outperform rating on December 11, 2023, and set its price target to $75. On April 20, 2023, Morgan Stanley initiated with a Overweight rating and assigned a price target of $80 on the stock. Goldman downgraded its rating to a Neutral and decreased its price target to $49 on August 22, 2022. Mizuho initiated its recommendation with a Buy and recommended $74 as its price target on July 07, 2022. UBS started tracking with a Buy rating for this stock on June 14, 2022, and assigned it a price target of $75. In a note dated April 22, 2022, Piper Sandler initiated an Neutral rating and provided a target price of $59 on this stock.
For the past year, the stock price of Intra-Cellular Therapies Inc fluctuated between $45.50 and $84.89. Currently, Wall Street analysts expect the stock to reach $75.5 within the next 12 months. Intra-Cellular Therapies Inc [NASDAQ: ITCI] shares were valued at $72.37 at the most recent close of the market. An investor can expect a potential return of 4.32% based on the average ITCI price forecast.
Analyzing the ITCI fundamentals
According to Intra-Cellular Therapies Inc [NASDAQ:ITCI], the company’s sales were 464.37M for trailing twelve months, which represents an 50.34% jump. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -0.34%, Pretax Profit Margin comes in at -0.3%, and Net Profit Margin reading is -0.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.23 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 70.68 points at the first support level, and at 68.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 74.31, and for the 2nd resistance point, it is at 76.25.
Ratios To Look Out For
It is important to note that Intra-Cellular Therapies Inc [NASDAQ:ITCI] has a current ratio of 5.41. As well, the Quick Ratio is 5.31, while the Cash Ratio is 1.2. Considering the valuation of this stock, the price to sales ratio is 15.19, the price to book ratio is 11.79.
Transactions by insiders
Recent insider trading involved Mates Sharon, Chairman, President & CEO, that happened on Mar 11 ’24 when 20565.0 shares were sold. SVP of Finance, CFO, Hineline Lawrence J. completed a deal on Mar 11 ’24 to sell 10121.0 shares. Meanwhile, EVP and General Counsel Halstead Michael sold 7345.0 shares on Mar 11 ’24.
